Note:This event is not part of the official Internal Medicine Meeting
2020 Education Program.
Internists play an integral role in the prevention and treatment of
macrovascular and microvascular complications in their patients
with type 2 diabetes. At the front line of diabetes management, they
are well-positioned to recommend to their patients therapies--SGLT2
inhibitors and GLP-1 RAs--which have been demonstrated in clinical
trials, and recommended in guidelines and scientific statements
from diabetes and cardiovascular societies, to reduce cardiorenal
risk. With the rapidly growing body of evidence with SGLT2 inhibitors,
there is a need for internists to interpret the latest findings and
the resultant changes in recommendations, and apply the evidence
and recommendations in clinical practice. In addition to prescribing
SGLT2 inhibitors for treatment of hyperglycemia, internists can help
ensure that their patients with type 2 diabetes have a reduced risk of
atherosclerotic cardiovascular disease (ASCVD) by prescribing them
as recommended in primary prevention guidelines from the American
College of Cardiology (ACC) and American Heart Association (AHA).
Internists can utilize SGLT2 inhibitors to reduce the risk of development
of nephropathy in their patients with type 2 diabetes; benefits have
been observed in cardiovascular outcomes trials (CVOTs) in patients
with normal or only mildly reduced renal function. In addition,
effectiveness in reducing the risk of hard renal outcomes has been
published with SGLT2 inhibition in patients with chronic kidney disease
(CKD). In patients with established ASCVD, SGLT2 inhibitors have
demonstrated reductions in the risk of major cardiovascular events
(MACE). Diabetes is a risk factor for heart failure (HF); prevention of
HF has been demonstrated with SGLT2 inhibitors in multiple clinical
trials. A clinical trial of patients with HF has indicated the benefit of
a SGLT2 inhibitor for treatment of HF in patients with and without
diabetes. The American Diabetes Association (ADA) now recommends
SGLT2 inhibitors--independently of baseline A1C or individualized
A1C target--for patients with indicators of high risk or established
ASCVD, CKD, or HF. Internists need to ensure that their patients are
taking these medications, through direct recommendations with their
patients or in their multidisciplinary, collaborative interactions. In this
educational initiative, experts from primary care, cardiology, and nephrology will interpret
the latest findings, elaborate current recommendations, and describe
best practices for the use of SGLT2 inhibitors.
Upon completion of this activity, attendees should be able to:
- Describe the glycemic and non-glycemic effects of SGLT2 inhibitors and
discuss their safety profile.
- Recognize and explain the rationale for changing focus in guidelines
and scientific statements to managing cardiorenal risk in patients with
type 2 diabetes.
- Interpret the results from cardiovascular and heart failure outcome
trials with SGLT2 inhibitors.
- Assess the evidence on renal endpoints from cardiovascular and renal
outcome trials with SGLT2 inhibitors.
- Indicate the pivotal role for internists in reducing cardiorenal risk in
patients with diabetes.
Target Audience: This educational activity is intended for internists and other primary care providers.
Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP
Accreditation and Credit Designation Statements:
Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians. Voxmedia LLC designates this live activity for a maximum
of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their
participation in the activity. Nurse practitioners may participate in this educational activitycand earn a certificate of
completion as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements. The National Commission on
Certification of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations
accredited by the ACCME.
It is the policy of Voxmedia to ensure fair-balance, independence,
objectivity, and scientific rigor in all directly or jointly sponsored
educational activities. All prospective faculty are required to
disclose any significant financial, other interest or relationship (1)
with any commercial interest producing, marketing, re-selling, or
distributing health care goods or services consumed by, or used
on, patients AND (2) with any commercial supporters prior to
participating in the planning of an activity or developing content.
Only then may faculty receive approval to participate, and are
expected to contribute evidence-based material and information.
Faculty are required to indicate areas of their presentation that are
based on professional opinion vs. guidelines, meta-analysis etc.
All information submitted will be peer-reviewed.
Americans with Disabilities Act
Voxmedia fully complies with the legal requirements of the ADA and
the rules and regulations thereof. If any participant of this activity is in
need of accommodation, please call and/or submit in writing to:
Voxmedia, 454 Morris Avenue, Springfield, New Jersey 07081 USA;